湖南景峰医药股份有限公司 2022 年第三季度报告 证券代码：000908 证券简称：景峰医药 公告编号：2022-064 湖南景峰医药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 湖南景峰医药股份有限公司 2022 年第三季度报告 一、主要财务数据 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 增减 | | 上年同期增减 | | 营业收入（元） | 209,812,385.67 | -14.79% | ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 402,009,285.92, representing a 28.22% increase compared to CNY 313,539,215.10 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was a loss of CNY 11,462,480.25, a decrease of 113.68% from a profit of CNY 83,787,020.29 in the previous year[21]. - The net cash flow from operating activities increased by 41.11% to CNY 59,346,453.34, compared to CNY 42,056,342.62 in the same period last year[21]. - The total assets at the end of the reporting period were CNY 1,683,030,524.52, down 6.10% from CNY 1,792,299,532.27 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company decreased by 3.65% to CNY 295,212,978.94 from CNY 306,389,794.75 at the end of the previous year[21]. - The basic earnings per share were CNY -0.0130, a decline of 113.66% from CNY 0.0952 in the same period last year[21]. - The weighted average return on net assets was -3.81%, a decrease of 8.95% from 5.14% in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY -13,461,960.78, an improvement of 80.40% compared to CNY -68,675,648.08 in the previous year[21]. - The company reported a net profit of CNY 12,158,927.09, a significant decrease from CNY 85,420,457.45 in the same period of 2021, representing a decline of approximately 85.7%[180]. - The total comprehensive income for the first half of 2022 was CNY 12,719,053.44, a sharp decline from CNY 85,467,774.20 in the first half of 2021, representing a decrease of approximately 85.1%[181]. Investment and R&D - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company is committed to developing high-barrier generic drugs and has made significant progress in the anti-tumor field, with several products obtaining consistency evaluation registration certificates[42]. - The company is enhancing its research and development capabilities by establishing platforms for liposomes and nano-emulsions, focusing on high-end formulations[43]. - The company has established a multi-dimensional product pipeline, aiming for a product structure ratio of 70% chemical drugs, 20% biological drugs, and 10% traditional Chinese medicine[43]. - The company has invested 200 million CNY in R&D for new technologies, focusing on sustainable production methods[90]. - The company plans to continue its focus on research and development to enhance its product offerings and market competitiveness in the upcoming periods[197]. Market and Sales Strategy - The company’s main business remains unchanged, focusing on pharmaceutical investments, biopharmaceutical technology R&D, and medical trade[31]. - The sales approach combines direct management with academic marketing, enhancing brand image and expanding market reach[34]. - The company is exploring new media and e-commerce for market expansion, aiming to penetrate deeper into third-party and OTC markets[34]. - The company achieved a revenue of 402.01 million yuan in the first half of 2022, representing a year-on-year growth of 28.22% due to the recovery in sales of its flagship product, Xin Nao Ning capsules[48]. - The pharmaceutical segment contributed ¥395,862,440.80, accounting for 98.47% of total revenue, with a growth of 53.56% from ¥257,796,475.82[56]. Environmental Compliance - Shanghai Jingfeng reported that all monitored pollutants are within the discharge standards, including pH value at 7.9, ammonia nitrogen at 1.34 mg/L, and chemical oxygen demand at 15.4 mg/L[87]. - The total nitrogen discharge was recorded at 4.86 mg/L, which is below the regulatory limit of 60 mg/L, indicating compliance with environmental standards[87]. - The company has achieved a compliance rate of 100% for all monitored pollutants, reflecting its commitment to environmental protection[87]. - The company has implemented stringent monitoring practices to ensure all emissions remain within regulatory limits[87]. - The company has established emergency response plans for environmental incidents and has reported them to higher environmental protection authorities[103]. Risk Management - The company faces various risks, including macroeconomic and market risks, which may impact its business operations[4]. - The company faces significant risks from national policy changes affecting the pharmaceutical industry, including price negotiations and procurement policies[73]. - The company is committed to closely monitoring policy changes and adapting to national pharmaceutical reforms to maintain sustainable development[73]. - The company will strengthen market monitoring and strategic reserves of bulk materials to mitigate the risk of raw material price fluctuations[74]. Corporate Governance - The company has not sold any major assets or equity during the reporting period[70][71]. - The company has maintained a good integrity status, with no overdue debts or unfulfilled court judgments[120]. - The company has not reported any significant impact on its financial indicators due to the share changes[144]. - The company has communicated the risks associated with the uncertainty of share transfer agreements due to ongoing disputes[137]. Future Outlook - The company is exploring acquisition opportunities to strengthen its market presence and product offerings[88]. - Future outlook includes potential market expansion strategies to enhance competitive positioning[88]. - The company plans to accelerate transformation and upgrade by enhancing R&D capabilities and speeding up new product launches[74].

Revenue and Profit - The company's revenue for Q1 2022 was CNY 181,402,884.35, representing a 50.08% increase compared to CNY 120,869,292.97 in the same period last year[4] - Net profit attributable to shareholders decreased by 87.88% to CNY 3,338,005.22 from CNY 27,546,229.31 year-on-year[4] - Net profit for Q1 2022 was CNY 12,166,960.10, down 36.6% from CNY 19,202,159.72 in Q1 2021[22] - The net profit attributable to the parent company was CNY 3,338,005.22, a decline of 87.9% compared to CNY 27,546,229.31 in the previous year[22] - The company reported a basic and diluted earnings per share of CNY 0.0038, down from CNY 0.0313 in the same quarter last year[23] Cash Flow - The net cash flow from operating activities dropped significantly by 97.18% to CNY 3,446,754.01, down from CNY 122,196,127.27 in the previous year[11] - Operating cash flow net amount was CNY 3,446,754.01, significantly lower than CNY 122,196,127.27 in Q1 2021[25] - The cash flow from investing activities increased by 14.09% to CNY 84,691,218.51, attributed to the disposal of equity in Jingze Bio[11] - The net cash flow from investment activities was 84,691,218.51 CNY, an increase from 74,233,389.56 CNY in the previous year[27] - The total cash inflow from financing activities was 152,867,000.00 CNY, while the cash outflow was 105,385,861.43 CNY, resulting in a net cash flow of -105,385,861.43 CNY[27] - The cash flow from the repayment of debts was 82,401,917.78 CNY, compared to 287,201,097.23 CNY in the previous year[27] Assets and Liabilities - The company's total assets decreased by 5.80% to CNY 1,688,403,554.35 compared to CNY 1,792,299,532.27 at the end of the previous year[5] - Total assets amounted to CNY 1,688,403,554.35, a decrease from CNY 1,792,299,532.27 in the previous period[20] - Current assets totaled CNY 653,190,562.90, down from CNY 677,509,437.99 at the beginning of the year, indicating a decrease of about 3.6%[17] - Non-current assets decreased from CNY 1,114,790,094.28 to CNY 1,035,212,991.45, representing a decline of approximately 7.1%[18] - Total liabilities were CNY 1,348,506,079.20, down from CNY 1,464,569,017.32, showing a reduction of about 7.9%[19] - The company's cash and cash equivalents decreased from CNY 172,176,813.40 to CNY 154,334,239.10, a decline of approximately 10.4%[17] - Accounts receivable slightly decreased from CNY 202,233,546.35 to CNY 200,082,506.86, a reduction of about 1.1%[17] - Inventory increased from CNY 155,396,312.61 to CNY 169,620,122.84, reflecting an increase of approximately 9.1%[17] - The company's short-term borrowings decreased from CNY 475,667,122.10 to CNY 422,903,579.38, a decline of about 11.1%[18] - The total equity remained stable at CNY 339,897,475.15, unchanged from the previous period[19] - The company reported a significant reduction in other payables from CNY 238,875,678.46 to CNY 205,702,671.21, a decrease of approximately 13.9%[19] Expenses - Research and development expenses were reduced by 43.90% to CNY 4,875,944.05 from CNY 8,692,269.11 year-on-year[10] - Research and development expenses decreased to CNY 4,875,944.05 from CNY 8,692,269.11, a reduction of 43.5%[20] - Sales expenses increased to CNY 85,251,973.55 from CNY 57,471,972.67, an increase of 48.4%[20] - The company reported a 101.07% increase in non-operating expenses, totaling CNY 6,898,999.53, primarily due to fixed asset disposals and inventory write-offs[10] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 85,930[12] - Other comprehensive income attributable to the parent company was CNY 3,337,358.11, compared to CNY 6,543,839.44 in the previous year[23]

Financial Performance - The company's operating revenue for 2021 was CNY 811,183,491.16, representing a decrease of 7.60% compared to 2020[19]. - The net profit attributable to shareholders was a loss of CNY 163,660,189.9, an improvement of 84.68% from the previous year's loss[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of CNY 477,230,162.4, a decrease of 62.91% compared to 2020[19]. - The net cash flow from operating activities was CNY 123,834,599.70, an increase of 145.58% compared to the previous year[19]. - The company's basic and diluted earnings per share for 2021 were both -0.186 yuan, showing an improvement of 84.63% compared to -1.21 yuan in 2020[20]. - The weighted average return on equity was -39.18% in 2021, an improvement from -101.39% in 2020, indicating a 62.21% increase[20]. - Total assets decreased by 33.37% to 1,792,299,532 yuan at the end of 2021, down from 2,690,276,316 yuan at the end of 2020[20]. - The company reported a total of 313,569,972.48 yuan in non-recurring gains and losses for 2021, up from 218,023,739.61 yuan in 2020[27]. - The company achieved a total revenue of 811.18 million yuan in 2021, a decrease of 7.60% compared to the previous year[49]. - The pharmaceutical segment generated 628.89 million yuan, accounting for 77.53% of total revenue, reflecting a decline of 14.95% year-on-year[51]. Operational Challenges and Outlook - The company reported a significant internal control deficiency in financial reporting during the reporting period[5]. - The company has faced challenges in its future operations, which are discussed in the management's outlook section[5]. - The audit report issued by the accounting firm included a qualified opinion[5]. - The company is committed to ensuring the accuracy and completeness of its financial reports[4]. - The company has not changed its main business since its listing[17]. Research and Development - The company is focusing on improving the quality of generic drugs through consistency evaluations, which is expected to enhance market competitiveness in the long term[31]. - The R&D model integrates self-research and collaborative development, with a focus on key areas and leveraging partnerships with global pharmaceutical companies for innovation[36]. - The company aims to focus on progressive innovations with clinical value, targeting major diseases and planning for patent expirations to strive for first-to-file generics[37]. - The company is actively developing new products and expanding its product pipeline, with several products already in clinical trials or having received clinical approval[39]. - The company is focusing on pediatric medications, addressing the limited availability of such products in the market, with specific formulations for common childhood ailments[41]. Marketing and Sales Strategy - The sales strategy combines self-operated and outsourced models, focusing on academic marketing and expanding the sales team to enhance market presence and efficiency[35]. - The company has established a comprehensive marketing network covering all 31 provinces, cities, and autonomous regions in China, enhancing its sales in both public and private hospitals[44]. - The company plans to enhance its marketing channels and expand its sales network to achieve sales targets for its heart and brain capsules[45]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities, with various pollutants being monitored and reported[157]. - All monitored pollutants, including pH, ammonia nitrogen, and chemical oxygen demand, have been reported to be within the discharge standards[157]. - The company has successfully maintained compliance with all environmental discharge standards, including total phosphorus and total nitrogen[157]. - The company has implemented measures to ensure that volatile organic compounds and particulate matter emissions are within acceptable limits[158]. - The company has a wastewater treatment capacity of 400 tons per day, operational since 2019, ensuring compliance with environmental standards[168]. Corporate Governance - The company maintained an independent business operation and governance structure, ensuring no interference from the controlling shareholder[106]. - The company has established a robust internal control system and governance structure, complying with relevant laws and regulations[109]. - The company has effectively communicated with investors through various channels, enhancing investor understanding and recognition[108]. - The company has a stable management team that adheres to established procedures for personnel appointments[108]. - The company has implemented measures to ensure fair and timely information disclosure, avoiding selective disclosure practices[108]. Financial Management and Investments - The company has adjusted its financial statements for 2020, recognizing an investment income of CNY 107,466,546.76 from the disposal of Haimen Huiju[191]. - The company acquired a 51% stake in Yibin Zhonglian Pharmaceutical Co., Ltd. for CNY 201,000 on January 28, 2021, and disposed of a 60% stake in Yunnan Liandong Co., Ltd. for CNY 32,920,000 on December 15, 2021[193]. - The company has retained the same accounting firm, Lixin Certified Public Accountants, for 8 years, with an audit fee of CNY 1,100,000 for the current period[194]. Employee Management - The total number of employees at the end of the reporting period was 846, with 49 in the parent company and 797 in major subsidiaries[135]. - The employee composition includes 405 production personnel, 222 technical personnel, and 13 sales personnel[135]. - The company has implemented a training plan aimed at enhancing professional capabilities and aligning with international standards in the generic drug industry[138]. - The company’s remuneration policy is designed to attract and retain core talent, focusing on value creation and distribution[136]. Risk Management - The company faces significant risks from policy changes in the pharmaceutical industry, which could impact production costs and profitability due to reforms in drug pricing and procurement[93]. - Fluctuations in raw material prices pose a risk to production costs, prompting the company to implement strategic reserves and develop key raw materials independently[94]. - The company is focused on mitigating R&D risks by establishing robust project management and incentive systems to ensure timely product development[99]. - Management risks associated with company expansion are being addressed by enhancing internal control systems and operational efficiency[100].

湖南景峰医药股份有限公司 2021 年第三季度报告 证券代码：000908 证券简称：景峰医药 公告编号：2021-091 湖南景峰医药股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保 证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 246,227,086.57 | -33.75% | 559,766,301.67 | -40.2 ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 313,539,215.10, a decrease of 44.49% compared to CNY 564,828,675.97 in the same period last year[20]. - The net profit attributable to shareholders was CNY 83,787,020.29, down 39.53% from CNY 138,553,429.36 year-on-year[20]. - The basic earnings per share decreased by 39.56% to CNY 0.0952 from CNY 0.1575 in the same period last year[20]. - The operating profit for the same period was 93.81 million yuan, down 41.98% year-on-year, while the net profit attributable to shareholders was 83.79 million yuan, a decline of 39.53%[35]. - The total profit for the first half of 2021 was CNY 85,148,299.06, down from CNY 158,144,264.64 in the first half of 2020, representing a decline of 46.1%[147]. - The total comprehensive income for the first half of 2021 was CNY 85,467,774.20, compared to CNY 132,303,592.32 in the first half of 2020, a decrease of 35.4%[148]. - The company's revenue from the pharmaceutical sector was approximately ¥257.80 million, a decrease of 17.20% year-over-year, with a gross margin of 76.15%, which is an increase of 25.93% compared to the previous year[48]. Cash Flow and Investments - The net cash flow from operating activities increased by 216.93%, reaching CNY 42,056,342.62, compared to a negative cash flow of CNY -35,967,711.91 in the previous year[20]. - The company reported a significant increase in cash flow from operating activities, amounting to ¥42.06 million, compared to a negative cash flow of ¥35.97 million in the previous period[44]. - The total cash inflow from investment activities reached ¥152,181,080.00, while cash outflow was ¥11,269,951.02, resulting in a net cash flow of ¥140,911,128.98 from investment activities[154]. - The company reported a significant increase in cash received from the disposal of subsidiaries, amounting to ¥140,800,000.00 in the first half of 2021[158]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,513,364,634.40, a decrease of 6.57% from CNY 2,690,014,013.86 at the end of the previous year[20]. - The company's total liabilities as of June 30, 2021, amounted to CNY 1,811,659,943.03, a decrease of 11.7% from CNY 2,051,835,713.87 at the end of 2020[140]. - The company's cash and cash equivalents decreased to CNY 105.30 million, representing 4.19% of total assets, down from 7.10% at the end of the previous year[52]. - The company's short-term borrowings were ¥794.92 million, which is 31.63% of total assets, a decrease from 23.69% the previous year[52]. Research and Development - The company has established a product structure target aiming for a ratio of 70% chemical drugs, 20% biological drugs, and 10% traditional Chinese medicine[36]. - The company is focusing on high-barrier generic drugs and has developed a diverse R&D pipeline, including high-end formulations and innovative drug research[36]. - The company's R&D investment decreased by 78.78% to ¥22.12 million from ¥104.24 million, reflecting a strategic reduction in funding[44]. - The company has a clear R&D strategy with a rich pipeline, including products in cardiovascular, oncology, and pain management fields, with several products in various stages of approval[40]. Market and Sales Strategy - The company operates in the pharmaceutical manufacturing industry, with a focus on cardiovascular, oncology, orthopedic, women's and children's health, digestive system, anti-infection products, and medical devices[27]. - The sales strategy combines self-operated and outsourced models, focusing on academic marketing and expanding into third-party and OTC markets[31]. - The company is focusing on marketing to tiered hospitals while expanding into private hospitals and lower-tier medical markets, anticipating stable sales growth[39]. - The company achieved a hospital coverage of over 1,000 for its anti-tumor drugs, with total hospital coverage exceeding 10,000, and expects to double this number in the next five years[40]. Risk Management - The company has faced various risks, including macroeconomic and market risks, which may impact its business operations[5]. - The company is facing significant risks from policy changes in the pharmaceutical industry, which could impact production costs and profitability due to reforms in drug pricing and procurement[59]. - The fluctuation in raw material prices poses a risk to production costs, prompting the company to strengthen market monitoring and strategic reserves[61]. - The company is focused on mitigating R&D risks by implementing a structured project management approach and enhancing its organizational framework[64]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[74]. - The company achieved a COD discharge of 20 mg/L, well below the standard of ≤500 mg/L, indicating compliance[74]. - The company reported a pH level of 7.58 for wastewater discharge, within the acceptable range of 6-9[74]. - The company has maintained normal operations for all pollution control facilities across its subsidiaries[76]. Corporate Governance - The company has appointed new independent directors and a financial director as of January 26, 2021[69]. - The company did not engage in any related party transactions during the reporting period[91]. - The company has not experienced any bankruptcy restructuring matters[88]. - The half-year financial report has not been audited[86]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 100,908[117]. - The largest shareholder, Ye Xiangwu, holds 15.01% of the shares, totaling 132,075,772 shares, with a decrease of 29,054,210 shares during the reporting period[118]. - The company did not implement any share buyback during the reporting period[113]. - The total number of shares held by directors and senior management is 133,241,710 shares after accounting for changes[120].

Business Performance - In 2020, Jingfeng Pharmaceutical achieved rapid business growth, capitalizing on opportunities in the Chinese pharmaceutical industry[5]. - The company's operating revenue for 2020 was ¥877,918,599.51, a decrease of 34.68% compared to ¥1,344,029,111.24 in 2019[22]. - The net profit attributable to shareholders was -¥969,922,381.52, representing a 7.88% decline from -¥882,806,468.65 in the previous year[22]. - The net cash flow from operating activities was -¥271,684,172.70, a significant drop of 851.12% compared to ¥36,170,428.51 in 2019[22]. - The total assets at the end of 2020 were ¥2,690,276,316.02, down 38.16% from ¥4,350,072,904.84 at the end of 2019[23]. - The net assets attributable to shareholders decreased by 72.08% to ¥442,774,825.95 from ¥1,585,604,781.55 in 2019[23]. - The company reported a basic earnings per share of -¥1.10, a 10% decrease from -¥1.00 in 2019[22]. - The company achieved a total revenue of 24,857.3 billion CNY in 2020, representing a year-on-year growth of 4.5%, which is 3.7 percentage points higher than the overall growth of large-scale industrial enterprises in the same period[37]. - The total profit reached 3,506.7 billion CNY, with a year-on-year increase of 12.8%, surpassing the average growth of 8.7% for large-scale industrial enterprises[37]. Research and Development - The company plans to focus on the development of high-barrier generic drugs and a multi-dimensional R&D production pipeline[5]. - The company emphasizes the importance of pharmaceutical innovation and core technology breakthroughs for future growth[5]. - The company has a product pipeline that includes unique offerings in cardiovascular, oncology, orthopedic, pediatric, digestive, and infection fields[31]. - The company emphasizes a research and development model that combines self-research and joint development, aiming for rapid breakthroughs in key areas[35]. - The company has established a stable internal and external research and development ecosystem through collaborations with universities and research institutions[35]. - The company is advancing the R&D of multiple international projects, including JS01, JS06, JS07, and others, with a focus on high-barrier generic drugs and innovative drug pipelines[54]. - The company has completed the II phase clinical trial for Fluorobiphenyl Ester Injection and is preparing for the III phase clinical trial[50]. - The company has a rich pipeline of products under research, including medical-grade hyaluronic acid gel and a new drug for cross-linked hyaluronic acid injection, with ongoing clinical trials[49]. - The company has established a research center to develop high-end formulations such as liposomes and nano-emulsions, enhancing its R&D capabilities[44]. - The company is actively conducting clinical research for its new drug projects, including JZB28 and JZB34, which are in the clinical research phase[64]. Financial Management - The company will not distribute cash dividends or bonus shares for the year[10]. - The audit report for the financial year was issued by Lixin Accounting Firm, confirming the accuracy of the financial statements[9]. - The company has maintained its main business without any changes since its listing[20]. - The company is actively improving its human resources management system to adapt to changes in the pharmaceutical industry[51]. - The company is focusing on integrating resources and optimizing asset allocation to enhance overall competitiveness[55]. - The company reported a significant increase in investment income of ¥330,760,362.07, accounting for 146.71% of total profit, primarily from the disposal of long-term equity investments[88]. - The company’s cash and cash equivalents decreased by 130.43% to -¥245,710,111.76 in 2020, reflecting the cumulative impact of reduced operating income and increased debt repayments[85]. - The company has received production administrative licenses for medical sodium hyaluronate gel (ophthalmology) and is steadily producing sodium hyaluronate series products[56]. - The company is preparing for the submission of supplementary application materials for several products, including Sodium Chloride Injection and Irinotecan Hydrochloride Injection[63]. Market Strategy - The company plans to increase its self-operated sales ratio to over 90% in the next five years, focusing on building a comprehensive sales network[34]. - The company is actively exploring the use of new media and e-commerce technologies for market expansion[34]. - The company is enhancing its marketing network and professional academic promotion to deepen market penetration[56]. - The company is committed to a multi-channel sales network, increasing its academic marketing efforts to enhance clinical influence[58]. - The marketing strategy focuses on professional self-operation as the main approach, supplemented by outsourcing and agency, aiming for deep marketing and market penetration[110]. Challenges and Risks - The company’s operational performance is subject to various risks, including macroeconomic and market risks[9]. - The company faced significant challenges due to the pandemic but continued to focus on foundational stability and steady development throughout 2020[32]. - The pharmaceutical manufacturing industry faced an average growth rate of approximately -11.2% in 2020 due to the pandemic, highlighting the challenges in the sector[37]. - The company is closely monitoring the impact of the COVID-19 pandemic on the pharmaceutical industry and adjusting strategies accordingly[118]. - The company is aware of potential tax policy changes that could increase tax burdens and is preparing to adapt to these changes[117]. Corporate Governance and Social Responsibility - The company has established a governance structure to protect the rights of shareholders and creditors, ensuring compliance with legal obligations[157]. - The company actively promotes employee rights and development, providing a platform for self-actualization and maintaining a harmonious corporate culture[158]. - The company emphasizes environmental responsibility, implementing measures for energy conservation and pollution reduction[159]. - The company engaged in charitable donations, including support for agricultural projects in Yunnan[160]. - The company is committed to poverty alleviation efforts, aligning its development with national strategies to support impoverished areas[161]. - In 2020, the company contributed a total of 5 million yuan to poverty alleviation efforts, focusing on targeted assistance to impoverished households[163]. Shareholder Information - The total number of shareholders at the end of the reporting period was 60,901, a decrease from 64,887 at the previous month-end[187]. - The largest shareholder, Ye Xiangwu, held 18.31% of the shares, with a reduction of 13,036,200 shares during the period[187]. - The company has not issued any new shares or conducted any share buybacks during the reporting period[186]. - The actual controller, Ye Xiangwu, remains unchanged and holds a significant influence over the company[190]. - The company has not reported any changes in major shareholders during the reporting period[189].

Financial Performance - The company's operating revenue for Q1 2021 was ¥120,869,292.97, a decrease of 60.73% compared to ¥307,774,671.77 in the same period last year[9] - Net profit attributable to shareholders was ¥27,546,229.31, representing a significant increase of 1,894.28% from ¥1,381,264.66 year-on-year[9] - Basic earnings per share rose to ¥0.0313, up 1,856.25% from ¥0.0016 in the same period last year[9] - The total operating costs for Q1 2021 were CNY 188.59 million, a decrease from CNY 309.47 million in the same period last year, representing a reduction of approximately 39%[41] - The net profit for Q1 2021 was CNY 19.20 million, compared to a net loss of CNY 7.44 million in Q1 2020, indicating a significant turnaround[42] - The total profit for Q1 2021 was CNY 21.50 million, compared to a total loss of CNY 2.53 million in Q1 2020, marking a significant improvement[42] - The operating profit for Q1 2021 was CNY 24.80 million, a recovery from an operating loss of CNY 1.66 million in the previous year[42] Cash Flow - The net cash flow from operating activities was ¥122,196,127.27, a decline of 249.25% compared to -¥81,875,651.10 in the previous year[9] - Cash and cash equivalents decreased by 39.73% to ¥98,952,894.06 from ¥164,196,069.51 due to repayment of maturing debts[16] - The total cash inflow from operating activities was CNY 296,548,898.02, an increase of 17.2% compared to CNY 253,053,256.10 in the previous period[50] - The net cash flow from operating activities was CNY 122,196,127.27, a significant recovery from a negative CNY 81,875,651.10 in the previous period[50] - Cash inflow from investment activities totaled CNY 83,318,080.00, compared to CNY 90,157,857.95 in the previous period[50] - The net cash flow from investment activities was CNY 74,233,389.56, recovering from a negative CNY 43,465,996.76[50] - Cash inflow from financing activities was CNY 152,867,000.00, down 41.7% from CNY 262,350,000.00[51] - The net cash flow from financing activities was negative CNY 257,404,227.60, compared to a positive CNY 28,936,944.25 in the previous period[51] - The ending cash and cash equivalents balance was CNY 98,952,894.06, down from CNY 309,724,694.41 in the previous period[51] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,601,147,745.90, down 3.31% from ¥2,690,276,316.02 at the end of the previous year[9] - Total liabilities due within one year increased by 399.12% to ¥476,203,488.07 from ¥95,408,325.32, mainly due to reclassification of bonds[16] - The company's total liabilities decreased from CNY 2,051,835,713.87 to CNY 1,960,961,144.59, a decrease of approximately 4.4%[34] - Current liabilities increased from CNY 1,470,982,182.54 to CNY 1,778,937,711.89, an increase of approximately 20.9%[34] - Non-current liabilities decreased significantly from CNY 580,853,531.33 to CNY 182,023,432.70, a decline of about 68.7%[34] - The total equity attributable to shareholders increased from CNY 442,774,825.95 to CNY 473,658,413.37, an increase of about 6.9%[35] Research and Development - Research and development expenses decreased by 66.52% to ¥8,692,269.11 from ¥25,959,419.27, indicating reduced investment in R&D[16] - The cumulative investment in the new R&D center project reached ¥111,722,000 as of March 31, 2021[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 64,887[12] - The largest shareholder, Ye Xiangwu, holds 17.75% of the shares, amounting to 156,129,982 shares, with 120,847,486 shares pledged[12] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[13] Other Financial Metrics - Non-recurring gains and losses totaled ¥89,853,928.15, with government subsidies contributing ¥7,189,937.94 and other non-operating income and expenses at -¥3,299,733.50[10] - Long-term equity investments decreased from CNY 146,761,012.77 to CNY 130,896,186.16, a decline of approximately 10.8%[33] - The company reported a tax expense of CNY 2.30 million for Q1 2021, down from CNY 4.90 million in the same period last year[42] - Other comprehensive income after tax for Q1 2021 was CNY 6.54 million, compared to a loss of CNY 0.12 million in Q1 2020[42] - The company recorded a credit impairment loss of CNY -0.32 million in Q1 2021, a significant improvement from a loss of CNY -9.84 million in Q1 2020[41] - The company has not undergone an audit for the first quarter report[56]

Financial Performance - Operating revenue for the reporting period was CNY 371,669,104.08, an increase of 8.09% year-on-year [7]. - Net profit attributable to shareholders was a loss of CNY 62,738,202.58, a decline of 69.54% compared to the same period last year [7]. - Basic earnings per share were CNY -0.0713, a decrease of 69.54% compared to the same period last year [7]. - The weighted average return on net assets was -3.71%, down from 4.76% in the previous year [7]. - The company reported a net profit attributable to shareholders of ¥75,815,226.78, a significant turnaround from a loss of ¥142,943,425.89 in the previous year, driven by investment income from Haimen Huiju [17]. - The net profit for the current period is ¥58,352,731.14, compared to a net loss of ¥164,490,818.74 in the previous period, showing a significant turnaround [52]. - The total comprehensive income for the current period is -74,175,754.03, compared to -216,600,460.65 in the previous period, reflecting a substantial reduction in losses [45]. Cash Flow and Liquidity - The net cash flow from operating activities was a negative CNY 84,247,392.62, worsening by 15.08% year-on-year [7]. - Cash and cash equivalents decreased by 32.42% to ¥274,039,467.30 due to reduced sales collections impacted by the pandemic [15]. - Operating cash inflows decreased by 51.49% to ¥821,736,457.96, significantly affected by the pandemic's impact on sales collections [18]. - The net cash flow from operating activities turned negative at -¥120,215,104.53, a decrease of 372.23% compared to the previous year [18]. - Cash and cash equivalents at the end of the period totaled ¥269,608,211.84, down from ¥1,119,651,442.40 at the end of the previous period [59]. - The ending cash and cash equivalents balance was $1.74 million, down from $7.15 million, a decrease of approximately 75.6% [64]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,976,746,110.01, a decrease of 8.58% compared to the end of the previous year [6]. - Total liabilities decreased to ¥2,129,093,827.08 from ¥2,408,265,982.28, a reduction of about 11.6% [37]. - The company’s total assets amounted to ¥5,902,376,829.40, a slight increase from ¥5,871,464,300.47 [40]. - Total current assets amounted to 20,920,020.69 million, with cash and cash equivalents at 4,222,408.18 million and other receivables at 12,800,369.97 million [71]. - Non-current assets totaled 5,850,544,279.78 million, including long-term equity investments of 5,792,807,787.87 million and intangible assets of 33,176,017.68 million [72]. - Total liabilities reached 1,117,063,241.35 million, with current liabilities at 729,019,041.35 million and non-current liabilities at 388,044,200.00 million [73]. Shareholder Information - The total number of shareholders at the end of the reporting period was 65,793 [10]. - The largest shareholder, Ye Xiangwu, held 19.80% of the shares, with 130,624,636 shares pledged [11]. - The company did not engage in any repurchase transactions during the reporting period [12]. Investments and Strategic Initiatives - The company signed a strategic cooperation agreement with Changde Economic and Technological Development Zone for pharmaceutical R&D and manufacturing [20]. - The company plans to invest ¥282 million in the construction of an international pharmaceutical industry park in Changde [20]. - The company completed the transfer of 43.0086% equity in Haimen Huiju for ¥320 million, impacting its financial position [19]. - The company has invested CNY 10,964.71 million in the "Jingfeng Pharmaceutical New R&D Center Project" as of September 30, 2020, continuing to utilize raised funds for this project [25]. Operational Costs and Expenses - Total operating costs amounted to ¥397,081,206.26, with operating costs specifically at ¥85,762,215.25, down from ¥119,012,279.74, reflecting a decrease of about 28.0% [43]. - The company incurred sales expenses of ¥3,577,131.67, with management expenses totaling ¥43,939,396.83 [55]. - The research and development expenses for the current period amount to ¥95,141,086.83, slightly down from ¥101,370,815.27 in the previous period [50]. - The financial expenses for the current period are ¥84,289,517.94, an increase from ¥66,887,837.06 in the previous period [52]. Other Financial Metrics - Non-operating income included CNY 219,571,541.61 from the disposal of non-current assets [8]. - Investment income increased by 187.06% to ¥222,632,255.61, mainly due to the disposal of Haimen Huiju [16]. - The company reported an investment loss of ¥3,383,318.03, a significant decline from the previous period's investment income of ¥66,150,721.52 [55]. - The company has no overdue commitments from actual controllers, shareholders, or related parties during the reporting period [22]. - The company has no securities or derivative investments reported during the period [23][24].

证券代码：000908 证券简称：景峰医药 公告编号：2020-053 湖南景峰医药股份有限公司 关于参加湖南辖区上市公司 2020 年度投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步强化与投资者的互动交流，使广大投资者能更深入全面地了解公司 情况，湖南景峰医药股份有限公司（下称"公司"）将参加由中国证券监督管理委 员会湖南监管局、湖南省上市公司协会与深圳市全景网络有限公司联合举办的 "湖南辖区上市公司 2020 年度投资者网上集体接待日"活动，现将有关事项公 告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台，采取网络远程的方式举行，投资者可以登陆"全景•路演天下"网站 （http://rs.p5w.net/）参与公司本次投资者网上集体接待日活动，活动时间为 2020 年 9 月 11 日（星期五）下午 15:00－17:00。 届时公司相关人员将与投资者进行在线沟通与交流，欢迎广大投资者积极参 与。 特此公告 湖南景峰医药股份有限公司董事会 2020 年 9 月 8 日 ...